Within the article Dr Mardis refers to the significant potential of NGS for disease detection and monitoring, and the subsequent impact on patient care. She explains, “NGS gives us this great advantage of generating data that is very comprehensive, yet available to us in a very short timeframe”. This extensive, patient specific data is key, particularly for individuals suffering with cancer, as it allows diagnoses and the subsequent implementation of personalized treatment plans based on the genomic make-up of the malignancy. However, such extensive data production also poses a hurdle, placing extreme demands on computational resources and bioinformatics expertise for data analysis and medical interpretation.
Throughout the interview Dr Mardis raises further interesting avenues for the future progression and implementation of NGS in the clinic. To read more, access the complete article (http://eu.idtdna.com/
For additional information on xGen Lockdown Probes and other NGS reagents, please visit www.idtdna.com. Follow us on twitter @idtdna (http://www.twitter.com/